Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes

Inclusion Criteria: * Patients aged 18-70 with impaired glucose tolerance (IGT). * Patients aged 18-70 diagnosed with type 2 diabetes mellitus (T2DM) deemed by the clinician not requiring pharmacological intervention. * Glycated hemoglobin (HbA1c) levels between 5.6% and 7.5%. * Voluntarily sign an informed consent form before the commencement of trial-related activities, understand the procedures and methods of the trial, and are willing and able to strictly adhere to the clinical trial protocol to complete the study. Exclusion Criteria: * Type 1 diabetes mellitus. * Known allergies to Sang Gua tablets or any of its components. * Use of hypoglycemic or lipid-lowering drugs within the last three months. * Presence of severe primary or secondary respiratory, cardiovascular, hepatic, or renal diseases, rheumatic connective tissue diseases, or hematological disorders. * Uncontrolled or unstable conditions exacerbated by infections, severe electrolyte imbalances, or other factors. * Patients with primary or secondary kidney diseases, hypertension, heart failure, acidosis, or urinary tract infections causing increased urinary protein, excepted. * Patients with psychiatric disorders. * Pregnant or planning to become pregnant women, or nursing mothers. * Patients requiring long-term steroid therapy. * Patients with poorly controlled hypertension or secondary hypertension. * Patients who have participated in other clinical trials within the past three months. * Patients deemed by the investigator as unsuitable for this clinical trial due to potential interference with trial results, impediments to full participation in the study, medical history, disease evidence, abnormal treatments, or laboratory values, or any other condition considered by the investigator to pose potential risks for participation in the study.